The effect of azithromycin on the pharmacokinetics of indinavir.
This study was performed to examine the effect of the coadministration of azithromycin on the pharmacokinetics of the protease inhibitor indinavir (Crixivan). In an open-label, parallel-design study, 32 healthy male and female volunteers were given indinavir (800 mg tid) for 5 days. One hour prior to the first dose of indinavir on day 5, 18 subjects received 1200 mg azithromycin (Zithromax), and 14 subjects received matching placebo. Serial samples of plasma were obtained for 8 hours following the morning dose of indinavir on days 4 and 5 and assayed for indinavir by HPLC/UV. Twenty-seven subjects completed the study. Following coadministration of azithromycin with indinavir, there was no significant change between day 5 and day 4 in AUC (20.7 mg.hr/ml and 23.1 mg.hr/ml; 90% CI on the ratio 81%-100%) or Cmax (9.88 mg/ml and 10.3 mg/ml; 90% CI 86%-108%). The day 5 to day 4 difference in indinavir concentrations following coadministration with azithromycin was not significantly different from the day 5 to day 4 difference with placebo (AUC p = 0.68; Cmax p = 0.074). Therefore, azithromycin does not significantly alter the kinetics of indinavir.
Foulds
G
G
Department of Clinical Pharmacology, Pfizer Central Research, Groton, Connecticut 06340, USA.
LaBoy-Goral
L
L
Wei
G C
GC
Apseloff
G
G
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology*; D019540:Area Under Curve; D017963:Azithromycin / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D010352:Patient Dropouts; D014839:Vomiting / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D017963:Azithromycin